Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

The CDA-AMC recommended that Ebglyss not be reimbursed by public drug plans, excluding Quebec, for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and ...

The CDA-AMC recommended that Ebglyss not be reimbursed by public drug plans, excluding Quebec, for the treatment of ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired ...

Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

An Auckland-based artist living with debilitating symptoms of topical steroid withdrawal (TSW) believes his dermatologists ...

If the patient has reported a history of steroid use, the first treatment step should be to discontinue the medication's use immediately. However, the patient should be aware that this may result ...